The role of metabolic syndrome and current approaches to the treatment and rehabilitation of patients with recurrent atypical endometrial hyperplasia and endometrial cancer

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Fertile age patients tend to have an increased prevalence of malignant neoplasms of the reproductive system. Metabolic syndrome (MS) is the main factor of endometrial hyperplasia with atypia, followed by possible tumor transformation. Obesity as part of MS supports chronic inflammation, metabolic disorders, oxidative stress, hyperestrogenemia, and persistent stimulation of endometrial cells. An integrated treatment approach should involve radical or organ-sparing surgery in reproductive-aged women, followed by hormonal therapy, as well as the comprehensive medical rehabilitation stage based on a multidisciplinary approach to prevent irreversible functional and mental disorders due to aggressive treatment methods and the disease itself.

Full Text

Restricted Access

About the authors

L. N. Sandzhieva

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: antoninasolopova@yandex.ru

A. G. Solopova

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: antoninasolopova@yandex.ru

доктор медицинских наук, профессор

D. V. Blinov

Institute of Preventive and Social Medicine; Lapino Clinical Hospital; F.P. Gaaz Moscow Sociomedical Institute

Email: antoninasolopova@yandex.ru

кандидат медицинских наук

E. E. Achkasov

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: antoninasolopova@yandex.ru

доктор медицинских наук, профессор

D. I. Korabelnikov

F.P. Gaaz Moscow Sociomedical Institute

Email: antoninasolopova@yandex.ru

кандидат медицинских наук

D. A. Petrenko

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Author for correspondence.
Email: antoninasolopova@yandex.ru

References

  1. Sung H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021; 71 (3): 209-49. doi: 10.3322/caac.21660
  2. Каприн А.Д., Старинский В.В., Шахзадова А.О. Злокачественные новообразования в России в 2020 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена -филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2021; 252 с.
  3. Sanderson P.A., Critchley H.O., Williams A.R. et al. New concepts for an old problem: the diagnosis of endometrial hyperplasia. Human Reprod Update. 2017; 23 (2): 232-54. doi: 10.1093/humupd/dmw042
  4. Setiawan V.W., Yang H.P., Pike M.C. et al. Type I. and II endometrial cancers: Have they different risk factors? J. Clin. Oncol. 2013; 31 (20): 2607-18. doi: 10.1200/JC0.2012.48.2596
  5. Murali R., Soslow R.A., Weigelt B. Classification of endometrial carcinoma: more than two types. Lancet Oncol. 2014; 15 (7): e268-78. doi: 10.1016/S1470-2045(13)70591-6
  6. Lacey J.V. Jr., Chia V.M. Endometrial hyperplasia and the risk of progression to carcinoma. Maturitas. 2009; 63 (1): 39-44. doi: 10.1016/j.maturitas.2009.02.005
  7. Secord A.A., Hasselblad V., Von Gruenigen V.E. et al. Body mass index and mortality in endometrial cancer: a systematic review and meta-analysis. Gynecol Oncol. 2016; 140 (1): 184-90. doi: 10.1016/j.ygyno.2015.10.020
  8. Jenabi E., Poorolajal J. The effect of body mass index on endometrial cancer: a metaanalysis. Public Health. 2015; 129 (7): 872-80. doi: 10.1016/j.puhe.2015.04.017
  9. Son J., Carr C., Yao M. et al. Endometrial cancer in young women: prognostic factors and treatment outcomes in women aged №40 years. Int J. Gynecol Cancer. 2020; 30 (5): 631-9. doi: 10.1136/ijgc-2019-001105
  10. Scherer P.E., Hill J.A. Obesity, diabetes, and cardiovascular diseases: a compendium. Circ Res. 2016; 118 (11): 1703-5. doi: 10.1161/CIRCRESAHA.116.308999
  11. Гаврилова Н.П., Селиверстов П.В., Айрапетян М.С. и др. Урсодезоксихолевая кислота в комбинации с менопаузальной гормональной терапией корригирует метаболические нарушения у женщин в менопаузе с неалкогольной жировой болезнью печени. Экспериментальная и клиническая гастроэнтерология. 2019; 8: 77-81. doi: 10.31146/1682-8658-ecg-168-8-77-81
  12. Cai J., Cui K., Niu F. et al. Genetics of IL6 polymorphisms: Case-control study of the risk of endometrial cancer. Mol Genet Genomic Med. 2019; 7 (4): e00600. doi: 10.1002/mgg3.600
  13. Vansaun M.N. Molecular Pathways: Adiponectin and leptin signaling in cancer. Clin Cancer Res. 2013; 19 (8): 1926-32. doi: 10.1158/1078-0432.CCR-12-0930
  14. Gao J., Tian J., Lv Y. et al. Leptin induces functional activation of cyclooxygenase-2 through JAK2/STAT3, MAPK/ERK, and PI3K/AKT pathways in human endometrial cancer cells. Cancer Sci. 2009; 100 (3): 389-95. doi: 10.1111/j.1349-7006.2008.01053.x
  15. Cymbaluk-Ploska A., Chudecka-Glaz A., Jagodzinska A. et al. Evaluation of biologically active substances promoting the development of or protecting against endometrial cancer. Onco Targets Ther. 2018; 11: 1363-72. doi: 10.2147/0TT.S155942
  16. Madeddu C., Sanna E., Gramignano G. et al. Correlation of Leptin, Proinflammatory Cytokines and Oxidative Stress with Tumor Size and Disease Stage of Endometrioid (Type I) Endometrial Cancer and Review of the Underlying Mechanisms. Cancers. 2022; 14 (2): 268. doi: 10.3390/cancers14020268
  17. Che Q., Liu B.Y., Wang F.Y. et al. Interleukin 6 promotes endometrial cancer growth through an autocrine feedback loop involving ERK-NF-kB signaling pathway. Biochem Biophys Res Commun. 2014; 446 (1): 167-72. doi: 10.1016/j.bbrc.2014.02.080
  18. Luo Y.Z., Yang Z., Qiu Y.L. et al. Pretreatment triglycerides-to-high density lipoprotein cholesterol ratio in postmenopausal women with endometrial cancer. Kaohsiung J. Med Sci. 2019; 35 (5): 303-9. doi: 10.1002/kjm2.12033
  19. Esposito K., Chiodini P., Capuano A. et al. Metabolic syndrome and endometrial cancer: a meta-analysis. Endocrine. 2014; 45 (1): 28-36. doi: 10.1007/s12020-013-9973-3
  20. Meireles C.G., Pereira S.A., Valadares L.P. et al. Effects of metformin on endometrial cancer: Systematic review and meta-analysis. Gynecol Oncol. 2017; 147 (1): 167-80. doi: 10.1016/j.ygyno.2017.07.120
  21. Acosta-Torres S., Murdock T. et al. The addition of metformin to progestin therapy in the fertility-sparing treatment of women with atypical hyperplasia/endometrial intraepithelial neoplasia or endometrial cancer: Little impact on response and low live-birth rates. Gynecol Oncol. 2020; 157 (2): 348-56. doi: 10.1016/j.ygyno.2020.02.008
  22. Falcone F., Laurelli G., Losito S. et al. Fertility preserving treatment with hysteroscopic resection followed by progestin therapy in young women with early endometrial cancer. J. Gynecol Oncol. 2017; 28 (2): e2. doi: 10.3802/jgo.2017.28.e2
  23. Yang B., Xu Y., Zhu Q. et al. Treatment efficiency of comprehensive hysteroscopic evaluation and lesion resection combined with progestin therapy in young women with endometrial atypical hyperplasia and endometrial cancer. Gynecol Oncol. 2019; 153 (1): 55-62. doi: 10.1016/j.ygyno.2019.01.014
  24. Giampaolino P., Sardo A.D.S., Mollo A. et al. Hysteroscopic Endometrial Focal Resection followed by Levonorgestrel Intrauterine Device Insertion as a Fertility-Sparing Treatment of Atypical Endometrial Hyperplasia and Early Endometrial Cancer: A Retrospective Study. J. Minim Invasive Gynecol. 2019; 26 (4): 648-56. doi: 10.1016/j.jmig.2018.07.001
  25. Fan Z., Li H., Hu R. et al. Fertility-Preserving Treatment in Young Women With Grade 1 Presumed Stage IA Endometrial Adenocarcinoma: A Meta-Analysis. Int J. Gynecol Cancer. 2018; 28 (2): 385-93. doi: 10.1097/IGC.0000000000001164
  26. Guillon S., Popescu N., Phelippeau J. et al. A systematic review and meta-analysis of prognostic factors for remission in fertility-sparing management of endometrial atypical hyperplasia and adenocarcinoma. Int J. Gynecol Obstet. 2019; 146 (3): 277-88. doi: 10.1002/ijgo.12882
  27. Wang Y., Yang J. Fertility-preserving treatment in women with early endometrial cancer: the Chinese experience. Cancer Manag Res. 2018; 10: 6803-13. doi: 10.2147/CMAR.S188087
  28. Frost J.A., Webster K.E., Bryant A. et al. Lymphadenectomy for the management of endometrial cancer. Cochrane Database Syst Rev. 2015; 2015 (9): CD007585. doi: 10.1002/14651858.CD007585.pub3
  29. Блбулян Т.А., Солопова А.Г., Иванов А.Е. и др. Влияние послеоперационной реабилитации на качество жизни больных раком вульвы. Акушерство, Гинекология и Репродукция. 2020; 14 (4): 415-25. doi: 10.17749/2313-7347/ob.gyn.rep.2020.156
  30. Власина А.Ю., Солопова А.Г., Сон Е.А. и др. Психоэмоциональное благополучие и сексуальная функция больных пограничными опухолями яичников. Акушерство, Гинекология и Репродукция. 2020; 14 (5): 551-67. doi: 10.17749/2313-7347/ob.gyn, rep.2020.147
  31. Солопова А.Г., Ачкасов Е.Е., Макацария А.Д. и др. Оценка сексуальной функции и вульвовагинальных симптомов у молодых пациенток с дистрофическими процессами вульвы. Акушерство, Гинекология и Репродукция. 2020; 14 (6): 622-9. doi: 10.17749/2313-7347/ob.gyn.rep.2020.127
  32. Бегович Е., Солопова А.Г., Хлопкова С.В. и др. Качество жизни и особенности психоэмоционального статуса больных наружным генитальным эндометриозом. Акушерство, Гинекология и Репродукция. 2022; 16 (2): 122-33. doi: 10.17749/2313-7347/ob.gyn.rep.2022.283
  33. Natavio K.M.A., Billod J.A. Sexual dysfunction among patients with endometrial cancer at a tertiary training public institution: A cross-sectional study. Philippine J. Obstet Gynecol. 2021; 45 (6): 223-8. doi: 10.4103/pjog.pjog_39_21
  34. Karatajli V., Can B., Qakir 1. et al. Life quality of endometrioid endometrial cancer survivors: a cross-sectional study. J. Obstet Gynaecol. 2021; 41 (4): 621-5. doi: 10.1080/01443615.2020.1787969
  35. Onujiogu N., Johnson, T., Seo. et al. Survivors of endometrial cancer: who is at risk for sexual dysfunction? Gynecol Oncol. 2011; 123 (2): 356-9. doi: 10.1016/j.ygyno.2011.07.035
  36. Heo J., Chun M., Oh Y.T. et al. Psychiatric comorbidities among endometrial cancer survivors in South Korea: a nationwide population-based, longitudinal study. J. Gynecol Oncol. 2019; 30 (2): e15. doi: 10.3802/jgo.2019.30.e15
  37. Власина А.Ю., Идрисова Л.Э., Солопова А.Г. и др. Реабилитация онкогинекологических больных после противоопухолевой терапии: пути решения. Акушерство, Гинекология и Репродукция. 2020; 14 (1): 44-55. doi: 10.17749/2313-7347.2020.14.1.44-55
  38. Солопова А.Г., Блинов Д.В., Бегович Е. и др. Неврологические расстройства после гистерэктомии: от патогенеза к клинике. Эпилепсия и пароксизмальные состояния. 2022; 14 (1): 54-64. doi: 10.17749/2077-8333/epi.par.con.2022.115
  39. Gao H., Xiao M., Bai H. et al. Sexual function and quality of life among patients with endometrial cancer after surgery. Int J. Gynecol Cancer. 2017; 27 (3): 608-12. doi: 10.1097/IGC.0000000000000905
  40. Рак тела матки и саркомы матки МКБ-10: C54. Клинические рекомендации Минздрава России. М., 2021.
  41. Блинов Д.В., Солопова А.Г., Плутницкий А.Н. и др. Организация здравоохранения в сфере реабилитации пациенток с онкологическими заболеваниями репродуктивной системы. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2022; 15 (1): 119-30. doi: 10.17749/2070-4909/farmakoekonomika.2022.132
  42. Коваленко Н.В., Жаворонкова В.В., Лысенко М.А. и др. Комплексная реабилитация пациенток после лечения рака эндометрия. Вопросы курортологии, физиотерапии и лечебной физической культуры. 2021; 98 (3-2): 89. doi: 10.17116/kurort20219803221
  43. Charlesworth E., Hughes J., Plant H. et al. Complementary therapy for people with cancer; the patient's perspective. Eur J. Integrative Med. 2018; 17: 26-32. DOI: 10.1016/j. eujim.2017.10.009
  44. Санджиева Л.Н., Солопова А.Г., Блинов Д.В. и др. Персонифицированная программа комплексной реабилитации после хирургического лечения рака эндометрия: результаты проспективного рандомизированного сравнительного исследования. Акушерство, Гинекология и Репродукция. 2022; 16 (2): 143-57. doi: 10.17749/2313-7347/ob.gyn.rep.2022.318

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies